Morgan Stanley Lowers Axon Enterprise (NASDAQ:AXON) Price Target to $675.00

Axon Enterprise (NASDAQ:AXON) had its price target decreased by equities research analysts at Morgan Stanley from $713.00 to $675.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Morgan Stanley’s price objective would suggest a potential upside of 23.72% from the stock’s current price.

Several other equities research analysts have also recently commented on AXON. Royal Bank Of Canada cut their price target on Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a research note on Wednesday. Barclays dropped their target price on Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating on the stock in a research report on Wednesday. The Goldman Sachs Group dropped their price objective on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Needham & Company LLC cut their price objective on Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Axon Enterprise in a research report on Monday, December 29th. Sixteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Axon Enterprise has a consensus rating of “Moderate Buy” and an average price target of $768.86.

Axon Enterprise Trading Up 23.3%

Shares of NASDAQ:AXON traded up $103.08 during mid-day trading on Wednesday, reaching $545.59. 1,496,956 shares of the company were exchanged, compared to its average volume of 955,195. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.12 and a quick ratio of 2.89. The firm has a market cap of $43.05 billion, a price-to-earnings ratio of 172.66, a P/E/G ratio of 12.76 and a beta of 1.48. Axon Enterprise has a 1 year low of $396.41 and a 1 year high of $885.91. The firm’s 50-day simple moving average is $539.81 and its 200 day simple moving average is $628.76.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.55. The business had revenue of $796.72 million for the quarter, compared to analysts’ expectations of $755.29 million. Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The business’s quarterly revenue was up 38.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.08 earnings per share. Equities research analysts forecast that Axon Enterprise will post 5.8 EPS for the current year.

Insider Buying and Selling

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $551.92, for a total value of $5,519,200.00. Following the completion of the sale, the chief executive officer directly owned 3,110,997 shares in the company, valued at $1,717,021,464.24. The trade was a 0.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Joshua Isner sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $552.60, for a total value of $11,052,000.00. Following the completion of the sale, the president directly owned 249,502 shares in the company, valued at $137,874,805.20. This trade represents a 7.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 48,040 shares of company stock worth $27,249,338. Insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

Hedge funds have recently made changes to their positions in the business. Stone House Investment Management LLC bought a new position in Axon Enterprise during the 3rd quarter worth $29,000. New Millennium Group LLC acquired a new stake in Axon Enterprise in the third quarter valued at $29,000. Darwin Wealth Management LLC acquired a new stake in Axon Enterprise during the 2nd quarter valued at approximately $37,000. Root Financial Partners LLC bought a new position in shares of Axon Enterprise in the 3rd quarter worth about $34,000. Finally, Creative Financial Designs Inc. ADV acquired a new position in shares of Axon Enterprise during the 4th quarter valued at $28,000. 79.08% of the stock is owned by institutional investors.

Key Stories Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beats and strong outlook — Axon reported Q4 revenue of about $797M (up ~39% YoY) and non‑GAAP EPS of $2.15, topping Street estimates; management set a 2026 growth outlook and introduced 2028 targets of $6B revenue and improved margins, driving optimism on top‑line momentum. Axon Enterprise beats fourth-quarter profit estimates, shares rise
• Positive Sentiment: AI bookings and product mix — Management cited accelerating AI-driven bookings across its device+software ecosystem, boosting recurring software revenue visibility and investor confidence in higher-margin growth. The maker of Taser stun guns says it’s becoming an AI company as bookings surge
• Positive Sentiment: Federal demand tailwind — Reports point to rising government spending (including DHS/body‑camera initiatives) and increased federal enforcement budgets that benefit Axon’s cameras, TASERs and evidence-management software. Analysts see this as a durable addressable market expansion. Axon shares rise as Taser-maker’s profit gets boost from government spending
• Neutral Sentiment: Analyst reaction — Some brokers reiterated or raised ratings (Needham maintained a Buy with a $600 PT), reflecting improved visibility; market commentary and earnings snapshots are circulating as investors re‑price expectations. Axon: Strong Q4 Momentum and Upgraded Long-Term Outlook Underpin Buy Rating
• Neutral Sentiment: Broader market context — Axon is appearing on “movers” lists as traders position for earnings and macro catalysts (AI names, Nvidia earnings) that can amplify intraday moves but don’t change company fundamentals. These Stocks Are Today’s Movers
• Negative Sentiment: Valuation and execution risk — Despite the beat, AXON still trades at a rich multiple and has faced sharp recent drawdowns amid AI‑related sentiment swings; some commentary warns the stock could fall if execution on aggressive 2028 targets slips. Can Axon Stock Fall To $300?

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.